Furthermore, the observed anti-lymphoma activity in this xenograft study, along with those observed with the following lymphoma xenograft pharmacology studies, confirmed that direct targeting tumor cell CD47 by HX009 resulted in anti-lymphoma effects without targeting CD47 on TME (e.g. those on immune cell, vascular cells, stromal cells, etc.)since the TME belongs to mouse components. The gene discussed is CD47; the disease is neoplasm.